Category Specific RSS

gary phillips

Syntara partners with University of Newcastle and ALLG to reduce blood transfusion dependence in blood cancer patients

Blood cancer patients undergoing chemotherapy could soon have a reduced dependence on blood transfusions thanks to a new clinical study…

2 years ago

Platinum Asset Management sees cancer treatment potential, boosts stake in Syntara to 19.24%

Heads have turned in biotech circles with an ASX filing confirming that Platinum Asset Management has increased its stake in…

2 years ago

Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib

Clinical stage drug development company Syntara (ASX:SNT) is set to get a big boost in exposure within the blood cancer…

2 years ago

Pharmaxis accelerates clinical drug developments with additional resources via sale of mannitol business to Arna Pharma

With a burgeoning pipeline of drugs deeply advanced, clinical stage biopharmaceuticals company Pharmaxis (ASX: PXS) has streamlined its business with…

2 years ago

Garvan Institute preclinical study identifies potential of Pharmaxis drug to boost pancreatic cancer survival rate by 35%

Each year, more than 4,000 Australians are diagnosed with pancreatic cancer, a form of cancer which is difficult to diagnose…

2 years ago

Pharmaxis delivers impressive Phase 2 clinical data to treat myelofibrosis, pushing on to FDA discussions

In a potential breakthrough for the field of bone marrow cancer treatment, biotech company Pharmaxis (ASX: PXS) has released the…

2 years ago